share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  09/10 10:33

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.
ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.
ZyVersa Therapeutics, Inc.已正式要求美国证券交易委员会(SEC)于2024年9月9日下午5:00生效其S-3表格的注册声明。该请求根据1933年修正的证券法第461条规定,通过EDGAR提交了一份函件。总部位于佛罗里达州韦斯顿的公司指出,如果有任何变动,生效日期和时间将可能更改,并会通知SEC。ZyVersa的CEO Stephen C. Glover签署了这一请求,公司的外部律师Faith L. Charles来自Thompson Hine LLP,负责与本事项相关的任何查询。
ZyVersa Therapeutics, Inc.已正式要求美国证券交易委员会(SEC)于2024年9月9日下午5:00生效其S-3表格的注册声明。该请求根据1933年修正的证券法第461条规定,通过EDGAR提交了一份函件。总部位于佛罗里达州韦斯顿的公司指出,如果有任何变动,生效日期和时间将可能更改,并会通知SEC。ZyVersa的CEO Stephen C. Glover签署了这一请求,公司的外部律师Faith L. Charles来自Thompson Hine LLP,负责与本事项相关的任何查询。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息